Form 4: TriSalus Director Mats Wahlstrom Receives Equity Grant

Director Mats Wahlstrom was granted restricted stock units and stock options as part of his 2026 board compensation package.

Summary

• Director Mats Wahlstrom received 37,602 restricted stock units (RSUs) vesting on May 14, 2027.
• Director Wahlstrom received 34,226 RSUs in lieu of his 2026 cash board retainer, vesting in equal quarterly installments through 2026.
• Director Wahlstrom was granted 75,204 stock options with an exercise price of $2.52, vesting on May 14, 2027.
• Following these transactions, the director's direct holdings increased to 87,555 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Director alignment with shareholder interests is strengthened through equity-based compensation.
• The election to receive RSUs in lieu of cash retainers demonstrates confidence in the company's long-term value.

Negatives

• The issuance of equity awards results in minor dilution to existing shareholders.

Risks

• Vesting of equity is contingent upon the director's continued service with the issuer.
• The value of the granted options is subject to market volatility and the company's future stock performance.

Future Outlook

The equity grants are subject to standard vesting schedules over the next year, aligning the director's incentives with the company's performance through May 2027.

Management Comments

• The director elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees.

Industry Context

StockSavvy.ai notes that it is standard practice for biotechnology and life sciences companies to utilize equity-based compensation to preserve cash reserves while incentivizing board members.

Comparison to Industry Standards

• The use of RSU-for-cash swaps is a common governance practice among small-cap biotech firms to maintain liquidity.
• The one-year cliff vesting schedule is consistent with standard director compensation policies in the life sciences sector.

Corporate Governance

Related Party Transactions

• The reporting person maintains indirect ownership through Leonard Capital LLC and HW Investment Partners, LLC.

Stakeholder Impact

• Shareholders experience minor dilution from the new equity issuance.

Next Steps

• Vesting of the Retainer RSU Award in quarterly installments throughout 2026.
• Vesting of the primary RSU Award and stock options on May 14, 2027.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Director Compensation, Equity Grant